[EN] ESTRADIOL-RELATED COMPOUNDS AND METHODS OF USE AS ANTI-TUMOR AGENTS [FR] COMPOSES SE RAPPORTANT A L'OESTRADIOL, ET PROCEDES D'UTILISATION COMME AGENTS ANTITUMORAUX
Estradiol-related compounds and methods of use as anti-tumor agents
申请人:Ho Shuk-Mei
公开号:US20060025394A1
公开(公告)日:2006-02-02
This invention relates to new estradiol-related compounds that can be used to treat various types of cancer including prostate and breast cancers.
本发明涉及可用于治疗包括前列腺癌和乳腺癌在内的各类癌症的新型雌二醇相关化合物。
Synthesis and Evaluation of (17α,20<i>Z</i>)-21-(4-Substituted-phenyl)-19-norpregna-1,3,5(10),20-tetraene-3,17β-diols as Ligands for the Estrogen Receptor-α Hormone Binding Domain: Comparison with 20<i>E</i>-Isomers
作者:Robert N. Hanson、Carolyn J. Friel、Robert Dilis、Alun Hughes、Eugene R. DeSombre
DOI:10.1021/jm040157s
日期:2005.6.1
As part of our ongoing program to develop probes for the hormone binding domain of the estrogen receptor-alpha (ER alpha), we prepared and evaluated a series of 17 alpha,Z-(4-substituted-phenyl)-vinyl estradiol derivatives. The results indicated that the relative binding affinities (RBAs) at 25 degrees C for the new compounds were significant (RBA = 9-57) although less than that of estradiol (RBA = 100) or of the parent unsubstituted phenylvinyl estradiol (RBA = 66). All of the Z-compounds were full agonists in the uterotrophic assay, indicating that the ligands formed estrogen-like complexes with the estrogen receptor-alpha hormone binding domain (ER alpha-HBD). Comparison of corresponding Z- and E-4-substituted phenylvinyl ligands complexed with the ER alpha-HBD indicated small but significant differences in binding modes that may account for the differing trends seen in the structure-activity relationships for the two series.
TRANSDERMAL DIETHYLSTILBESTROL FOR TREATING PROSTATE CANCER
申请人:Beer Tomasz M.
公开号:US20100016445A1
公开(公告)日:2010-01-21
Methods for treating prostate cancer comprising transdermally administering a therapeutically effective amount of diethylstilbesterol (DES), or a pharmaceutically acceptable salt or complex thereof, to a subject. In one embodiment, transdermally administered DES may be used to treat hot flashes in castrate prostate cancer patients. In another embodiment, transdermal DES may be administered as a therapy while avoiding testosterone surge and clinical tumor flare (for example, for treating symptomatic locally advanced prostate cancer, treating metastatic prostate cancer, or in a subject who is contraindicated for conventional therapy such as ADT therapy, particularly GnRH (gonadotropin-releasing hormone) therapy). In a further embodiment, transdermal DES may be administered to treat osteoporosis in men with prostate cancer. The transdermal DES may be used as a front line hormonal therapy or a second line hormonal therapy for treating prostate cancer.
[EN] ESTRADIOL-RELATED COMPOUNDS AND METHODS OF USE AS ANTI-TUMOR AGENTS<br/>[FR] COMPOSES SE RAPPORTANT A L'OESTRADIOL, ET PROCEDES D'UTILISATION COMME AGENTS ANTITUMORAUX